Massachusetts Life Sciences Center02.24.17
Visiomed, a French developer and provider of medical grade connected devices and services, is changing the landscape of healthcare with its use of technology providing patients with pro-active, custom-made solutions. Recognizing the rising demand of self-monitoring alongside the desire for instant and affordable healthcare without walls, Visiomed has launched BewellConnect, an ecosystem of high-level devices developed with healthcare professionals that is empowering the lives of patients.
Visiomed recently opened the first North American BewellConnect headquarters in the Back Bay neighborhood in downtown Boston, Mass.
“BewellConnect is at the forefront of the telemedicine industry and we are excited to produce significant advances in the healthcare industry,” said Olivier Hua, general manager of Visiomed Group and CEO of BewellConnect Corp. “By creating alliances with the industry, establishing our presence in the region, we hope to change how people monitor their healthcare and improve their quality of life.”
In the United States, BewellConnect is informing the future of health care by providing patients with alternative solutions that aim to help reduce the number of visits to the doctor, lessen the probability of hospital readmission, curtail health risks, promote prevention through daily self-monitoring, and streamline the communication with medical professionals since the patient is more informed of their own body.
“As a company constantly shifting and breaking industry norms, we want to join forces with life science innovators in the U.S. to change the treatment paradigm for people with chronic diseases and take the first steps towards self-monitoring medical devices,” says Eric Sebban, CEO of Visiomed Group.
“I am happy to welcome Visiomed to Boston, and am pleased they have chosen our city for their first North American headquarters," said Mayor Martin J. Walsh. "Boston is a global leader in healthcare, and I look forward to including BewellConnect to our roster of innovative, forward-thinking and fast-growing companies."
“Visiomed works at the intersection of medical devices and digital health, and they are a welcome addition to our innovation economy,” said Massachusetts Housing & Economic Development Secretary Jay Ash. “Telemedicine holds great promise for both improved patient outcomes and experience, and for meaningful savings in our health care system. We are glad to see Visiomed putting down roots in Massachusetts, and look forward to their future growth in the Commonwealth.”
“We are pleased to welcome Visiomed to Massachusetts and congratulate them on opening the first North American BewellConnect Headquarters in Boston,” said Robert K. Coughlin, president and CEO of MassBio. “We know that Visiomed will bring value to and benefit from our innovative healthcare ecosystem as they connect with new partners and work to improve patients’ lives.”
“Visiomed is developing technologies that have the potential both to improve patient care, and reduce health care costs through improved home monitoring and prevention,” said Travis McCready, president and CEO of the Massachusetts Life Sciences Center. “We welcome the company’s decision to advance these technologies here in Massachusetts, where innovation is transforming health care delivery.”
Founded by Eric Sebban in 2007, VISIOMED GROUP specializes in next-generation medical electronics. The laboratory develops and markets healthcare products in the areas of self-diagnosis for medical use and well-being. VISIOMED is also the inventor of the ThermoFlash, the first contactless medical infrared thermometer. VISIOMED products combine innovation, technology and design to non-drug prevention and treatment solutions focusing on simplicity, comfort and well-being for users. In 2014, VISIOMED GROUP announced the launch of its “BewellConnect” range of connected healthcare products, thus becoming the first medical electronics laboratory to penetrate the market of the Internet of Things (IoT).
Based in Paris, France, VISIOMED GROUP relies on a team of 105 employees, with a sales force dedicated to commercialisation through pharmacies (OTC), to health professionals (hospitals, clinics, retirement homes) and, since late 2010, in retail shops. In 2015, the Group achieved a turnover of more than 10 million euros.
Visiomed recently opened the first North American BewellConnect headquarters in the Back Bay neighborhood in downtown Boston, Mass.
“BewellConnect is at the forefront of the telemedicine industry and we are excited to produce significant advances in the healthcare industry,” said Olivier Hua, general manager of Visiomed Group and CEO of BewellConnect Corp. “By creating alliances with the industry, establishing our presence in the region, we hope to change how people monitor their healthcare and improve their quality of life.”
In the United States, BewellConnect is informing the future of health care by providing patients with alternative solutions that aim to help reduce the number of visits to the doctor, lessen the probability of hospital readmission, curtail health risks, promote prevention through daily self-monitoring, and streamline the communication with medical professionals since the patient is more informed of their own body.
“As a company constantly shifting and breaking industry norms, we want to join forces with life science innovators in the U.S. to change the treatment paradigm for people with chronic diseases and take the first steps towards self-monitoring medical devices,” says Eric Sebban, CEO of Visiomed Group.
“I am happy to welcome Visiomed to Boston, and am pleased they have chosen our city for their first North American headquarters," said Mayor Martin J. Walsh. "Boston is a global leader in healthcare, and I look forward to including BewellConnect to our roster of innovative, forward-thinking and fast-growing companies."
“Visiomed works at the intersection of medical devices and digital health, and they are a welcome addition to our innovation economy,” said Massachusetts Housing & Economic Development Secretary Jay Ash. “Telemedicine holds great promise for both improved patient outcomes and experience, and for meaningful savings in our health care system. We are glad to see Visiomed putting down roots in Massachusetts, and look forward to their future growth in the Commonwealth.”
“We are pleased to welcome Visiomed to Massachusetts and congratulate them on opening the first North American BewellConnect Headquarters in Boston,” said Robert K. Coughlin, president and CEO of MassBio. “We know that Visiomed will bring value to and benefit from our innovative healthcare ecosystem as they connect with new partners and work to improve patients’ lives.”
“Visiomed is developing technologies that have the potential both to improve patient care, and reduce health care costs through improved home monitoring and prevention,” said Travis McCready, president and CEO of the Massachusetts Life Sciences Center. “We welcome the company’s decision to advance these technologies here in Massachusetts, where innovation is transforming health care delivery.”
Founded by Eric Sebban in 2007, VISIOMED GROUP specializes in next-generation medical electronics. The laboratory develops and markets healthcare products in the areas of self-diagnosis for medical use and well-being. VISIOMED is also the inventor of the ThermoFlash, the first contactless medical infrared thermometer. VISIOMED products combine innovation, technology and design to non-drug prevention and treatment solutions focusing on simplicity, comfort and well-being for users. In 2014, VISIOMED GROUP announced the launch of its “BewellConnect” range of connected healthcare products, thus becoming the first medical electronics laboratory to penetrate the market of the Internet of Things (IoT).
Based in Paris, France, VISIOMED GROUP relies on a team of 105 employees, with a sales force dedicated to commercialisation through pharmacies (OTC), to health professionals (hospitals, clinics, retirement homes) and, since late 2010, in retail shops. In 2015, the Group achieved a turnover of more than 10 million euros.
